FR2895086B1 - Potentialisation de l'apoptose par des anticorps monoclonaux - Google Patents

Potentialisation de l'apoptose par des anticorps monoclonaux

Info

Publication number
FR2895086B1
FR2895086B1 FR0512815A FR0512815A FR2895086B1 FR 2895086 B1 FR2895086 B1 FR 2895086B1 FR 0512815 A FR0512815 A FR 0512815A FR 0512815 A FR0512815 A FR 0512815A FR 2895086 B1 FR2895086 B1 FR 2895086B1
Authority
FR
France
Prior art keywords
potentiation
apoptosis
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0512815A
Other languages
English (en)
Other versions
FR2895086A1 (fr
Inventor
Nathalie Fournier
Romeuf Christophe De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0512815A priority Critical patent/FR2895086B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to US12/097,686 priority patent/US20090305228A1/en
Priority to AU2006328798A priority patent/AU2006328798B2/en
Priority to BRPI0619994-1A priority patent/BRPI0619994A2/pt
Priority to PCT/FR2006/002767 priority patent/WO2007071839A2/fr
Priority to CA002633331A priority patent/CA2633331A1/fr
Priority to CNA2006800529235A priority patent/CN101375160A/zh
Priority to JP2008545047A priority patent/JP2009519302A/ja
Priority to EP06841970A priority patent/EP1969368A2/fr
Priority to KR1020087017266A priority patent/KR20080106164A/ko
Publication of FR2895086A1 publication Critical patent/FR2895086A1/fr
Priority to IL192195A priority patent/IL192195A0/en
Application granted granted Critical
Publication of FR2895086B1 publication Critical patent/FR2895086B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
FR0512815A 2005-12-16 2005-12-16 Potentialisation de l'apoptose par des anticorps monoclonaux Expired - Fee Related FR2895086B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0512815A FR2895086B1 (fr) 2005-12-16 2005-12-16 Potentialisation de l'apoptose par des anticorps monoclonaux
EP06841970A EP1969368A2 (fr) 2005-12-16 2006-12-15 Potentialisation de l' apoptose par des anticorps monoclonaux
BRPI0619994-1A BRPI0619994A2 (pt) 2005-12-16 2006-12-15 potencialização da apoptose por anticorpos monoclonais
PCT/FR2006/002767 WO2007071839A2 (fr) 2005-12-16 2006-12-15 Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 %
CA002633331A CA2633331A1 (fr) 2005-12-16 2006-12-15 Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 %
CNA2006800529235A CN101375160A (zh) 2005-12-16 2006-12-15 由单克隆抗体产生的凋亡增强
US12/097,686 US20090305228A1 (en) 2005-12-16 2006-12-15 Potentiation of Apoptosis by Monoclonal Antibodies
AU2006328798A AU2006328798B2 (en) 2005-12-16 2006-12-15 Potentiation of apoptosis by monoclonal antibodies
KR1020087017266A KR20080106164A (ko) 2005-12-16 2006-12-15 모노클로날 항체에 의한 아포톱시스의 강화
JP2008545047A JP2009519302A (ja) 2005-12-16 2006-12-15 モノクローナル抗体によるアポトーシスの増強作用
IL192195A IL192195A0 (en) 2005-12-16 2008-06-15 Potentiation of apoptosis by monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0512815A FR2895086B1 (fr) 2005-12-16 2005-12-16 Potentialisation de l'apoptose par des anticorps monoclonaux

Publications (2)

Publication Number Publication Date
FR2895086A1 FR2895086A1 (fr) 2007-06-22
FR2895086B1 true FR2895086B1 (fr) 2012-10-05

Family

ID=36932747

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0512815A Expired - Fee Related FR2895086B1 (fr) 2005-12-16 2005-12-16 Potentialisation de l'apoptose par des anticorps monoclonaux

Country Status (11)

Country Link
US (1) US20090305228A1 (fr)
EP (1) EP1969368A2 (fr)
JP (1) JP2009519302A (fr)
KR (1) KR20080106164A (fr)
CN (1) CN101375160A (fr)
AU (1) AU2006328798B2 (fr)
BR (1) BRPI0619994A2 (fr)
CA (1) CA2633331A1 (fr)
FR (1) FR2895086B1 (fr)
IL (1) IL192195A0 (fr)
WO (1) WO2007071839A2 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU3827099A (en) * 1998-05-08 1999-11-29 Universite Catholique De Louvain Apoptosis of naive human nk cells by crosslinking of their fcgammariiia molecules wiht a rat igg2b (lo-cd2a/bti-322) or its igg1 humanized monoclonal antibody
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7595165B2 (en) * 2002-09-13 2009-09-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method of measuring activation of effector cells
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs

Also Published As

Publication number Publication date
AU2006328798A1 (en) 2007-06-28
CA2633331A1 (fr) 2007-06-28
EP1969368A2 (fr) 2008-09-17
BRPI0619994A2 (pt) 2011-10-25
CN101375160A (zh) 2009-02-25
FR2895086A1 (fr) 2007-06-22
JP2009519302A (ja) 2009-05-14
IL192195A0 (en) 2008-12-29
WO2007071839A3 (fr) 2007-08-23
KR20080106164A (ko) 2008-12-04
AU2006328798B2 (en) 2012-02-09
US20090305228A1 (en) 2009-12-10
WO2007071839A2 (fr) 2007-06-28

Similar Documents

Publication Publication Date Title
FR23C1029I2 (fr) Compositions d'anticorps anti-ctla-4
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
IL189788A0 (en) Human monoclonal antibodies to cd70
IL191340A (en) Monoclonal antibodies against e8o
FR15C0048I2 (fr) Anticorps antagonistes de il-17
HK1151535A1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer -18
ATE483732T1 (de) Madcam-antikörper
ZA200802641B (en) Human monoclonal antibodies to CD70
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
ITMI20052486A1 (it) Procedimento di sintesi di intermedi per la preparazione di astaxantina
MA29014B1 (fr) Formulations d'anticorps
FR2921928B1 (fr) Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
DK1847524T3 (da) Terphenylderivater til behandling af Alzheimers sygdom
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
ITMI20052320A1 (it) Dispositivo di regolazione dell'altezza di selle o manubri
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
FR2920062B1 (fr) Architecture distribuee pour l'ensemble des aides a la radionavigation
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
FR2895086B1 (fr) Potentialisation de l'apoptose par des anticorps monoclonaux
LU91285B1 (fr) Couvercle hygiénique pour canette
BRPI0813520A2 (pt) Anticorpo monoclonal citotóxico anticâncer
FR2890528B1 (fr) Attache de maintien pour pieds de vigne
ZA200804254B (en) Human monoclonal antibodies to O8E

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20140829